Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Nephrology > Primary Hyperoxaluria Precision Panel

Primary Hyperoxaluria Precision Panel

Primary Hyperoxaluria (PH) is a group of inherited metabolic diseases of the liver characterized by increased formation of calcium-oxalate stones in kidneys with the subsequent development of nephrolithiasis and chronic kidney disease.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Primary Hyperoxaluria (PH) is a group of inherited metabolic diseases of the liver characterized by increased formation of calcium-oxalate stones in kidneys with the subsequent development of nephrolithiasis and chronic kidney disease. Hyperoxaluria is defined as elevated urinary excretion of oxalate (more than 40mg in 24 hours), a metabolic end product. This elevated excretion can contribute to the formation of kidney stones and other health problems. Mutations in specific liver enzymes involved in the oxalate metabolism make up the etiology of this disease. There are three main types of PH – PH types I, II and III – differentiated by the specific enzyme that is deficient.  

  • The Igenomix Primary Hyperoxaluria Precision Panel can be used to make a directed and accurate diagnosis and aid in the differential diagnosis of recurrent kidney stones ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Primary Hyperoxaluria Syndrome Precision Panel is indicated for those patients with a clinical suspicion or diagnosis of Primary Hyperoxaluria presenting with: 
    • Lower back pain 
    • Hematuria (blood in urine)   
    • Pain while urinating  
    • Inability to urinate 
    • Increased frequency of urination 
    • Fever/chills 
    • Foul smelling urine or cloudy looking urine 
    • Recurrent kidney stones or urinary tract stones 
    • Family history of recurrent kidney stones 
    • Any patient with renal failure of unknown cause 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.
  • Early initiation of treatment with a multidisciplinary team in the form of medical care to reduce oxalate levels, appropriate hydration and diet changes. 
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Shah, O., Holmes, R. P., & Assimos, D. G. (n.d.). Management of patients with hyperoxaluria. Urinary Stone Disease, 103-119. doi:10.1007/978-1-59259-972-1_7 

Hoppe, B., Beck, B. B., & Milliner, D. S. (2009). The primary hyperoxalurias. Kidney International, 75(12), 1264-1271. doi:10.1038/ki.2009.32 

Filippova, T. V., Svetlichnaya, D. V., Rudenko, V. I., Alyaev, Y. G., Shumikhina, M. V., Azova, M. M., Subbotina, T. I., Gadzhieva, Z. K., Asanov, A. Y., & Litvinova, M. M. (2019). Urologiia (Moscow, Russia : 1999), (5), 140–143. 

Milliner, D. (2006). Treatment of the primary hyperoxalurias: A new chapter. Kidney International, 70(7), 1198-1200. doi:10.1038/sj.ki.5001821 

Straub, M., Hautmann, R. E., Hesse, A., & Rinnab, L. (2005). Kalciumoxalatharnsteine und hyperoxalurie. Der Urologe, 44(11), 1315-1323. doi:10.1007/s00120-005-0936-z 

descargar

Detail description

Download

Request Information


WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Country/Region

[2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

Request Information


  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

International
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy